ID
31009
Description
Study ID: 104505 Clinical Study ID: BEX104505 Study Title: Phase II Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00950755 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin Complete this form for each clinical lab for which data are reported on case report forms. For data reported from outside institutions, please obtain the reference ranges and lab certification documentation. Use same Lab ID number on all laboratory forms. The form only needs to be completed once for each lab unless ranges or units change.
Keywords
Versions (1)
- 7/10/18 7/10/18 -
Copyright Holder
see clinicaltrials.gov
Uploaded on
July 10, 2018
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Iodine 131 B1 Antibody for B-Cell Lymphomas NCT00950755
Laboratory Reference Ranges
- StudyEvent: ODM
Similar models
Laboratory Reference Ranges
- StudyEvent: ODM
C0237753 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,2])
No comments